Beam Therapeutics Inc.
NASDAQ:BEAM
Overview | Financials
| Company Name | Beam Therapeutics Inc. |
| Symbol | BEAM |
| Currency | USD |
| Price | 19.94 |
| Market Cap | 2,017,170,280 |
| Dividend Yield | 0% |
| 52-week-range | 13.525 - 35.25 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. John M. Evans M.B.A. |
| Website | https://www.beamtx.com |
An error occurred while fetching data.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD









